Stay updated on Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2Fe3tX60Ubmif3kPofuee9vnYpup0.uncropped.jpg&w=3840&q=75)
Latest updates to the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content version.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Show more Revision: v2.9.0' has been updated to 'Show less Show less MedlinePlus related topics: Vaccines Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : ISA101 + Nivolumab HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1. Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose. There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond. Biological : ISA 101 100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1. Drug : Nivolumab 3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.' This change represents an update in the study details and treatment information for the clinical trial.SummaryDifference29%
Stay in the know with updates to Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.